EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

A functional comparison of vanzacaftor/tezacaftor/deutivacaftor and elexacaftor/tezacaftor/ivacaftor in patient-derived intestinal organoids with rare CFTR variants

Suzanne Kroes, Lara Zaidi, Heleen N Sonneveld-van Kooten, Lianne Winkel, Kris De Boeck, Margarida Amaral, Cornelis K van der Ent, Jeffrey M Beekman, Sacha Spelier, HIT-CF Organoid Study group

Journal of Cystic Fibrosis · 2026

DOI: 10.1016/j.jcf.2026.06.002 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Suzanne Kroes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Regenerative Medicine Utrecht, University Medical Center, Utrecht University, 3584 CT, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis, Benzodioxoles, Quinolones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 European Innovation Council Fast Track to Innovation, Dutch Cystic Fibrosis Foundation, Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cystic fibrosis (CF) results from pathogenic CFTR variants that impair epithelial chloride and bicarbonate transport. CFTR modulators such as elexacaftor/tezacaftor/ivacaftor (ETI) have transformed CF care, and the next-generation regimen vanzacaftor/tezacaftor/deutivacaftor (VTD) has recently been introduced on the market. VTD offers once-daily dosing and expanded regulatory approval, yet its functional advantages remain not fully characterized across a broad set of genotypes. Consequently, we set out to compare CFTR functional rescue of ETI and VTD in primary patient-derived intestinal organoids (PDIOs) harbouring a broad range of CFTR variants. METHODS: We evaluated ETI and VTD efficacy in 62 PDIO lines representing 42 rare CFTR genotypes and reference groups (p.Phe508del/p.Phe508del, p.Phe508del/class I, class I/class I). CFTR rescue was assessed by CFTR function by steady-state lumen area quantification and forskolin-induced swelling assays and CFTR maturation via western blot. RESULTS: Across rare variants, CFTR functional rescue by ETI and VTD strongly correlated, with modest but consistent VTD advantages in a subset of folding-defective genotypes (e.g., p.Val520Phe). Three PDIOs showed disproportionately high responses to VTD. VTD increased CFTR maturation more effectively than ETI, yet demonstrated similar acute effects on CFTR function. CONCLUSIONS: VTD provides modest genotype-specific functional advantages and enhanced CFTR maturation but is largely comparable to ETI across rare variants. PDIO-based screenings performed in this study underline again their potential for theratyping, which is particularly critical for guiding decisions on accessibility for rare variants in an era with a variety of modulators, and combinations thereof.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic Fibrosis Transmembrane Conductance RegulatorCystic FibrosisBenzodioxolesQuinolonesAminophenolsOrganoidsIndolesPyridinesHumansDrug CombinationsChloride Channel AgonistsPyrazolesQuinolinesSpiro Compounds

Stichwörter der Autor:innen

AlyftrekCFTR modulator therapiesCystic fibrosisForskolin-induced swelling assayPatient-derived intestinal organoidsRare genotypesTrikafta

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorBenzodioxolesQuinolonesAminophenolsDrug CombinationsIndolesChloride Channel AgonistsCFTR protein, humanelexacaftor, ivacaftor, tezacaftor drug combinationPyridines

Autor:innen und Institutionen

  • Regenerative Medicine Utrecht, University Medical Center, Utrecht University, 3584 CT, Utrecht, the Netherlands.
  • Department of Development and Regeneration, Woman and Child Unit, CF Research Lab, KU Leuven, Leuven, Belgium; Department of Pediatrics, Pediatric Pulmonology, University Hospital Leuven, Leuven, Belgium.
  • BioISI-Biosystems Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, 1749-016, Lisboa, Portugal.
  • Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, 3584 EA, Utrecht, the Netherlands.
  • Regenerative Medicine Utrecht, University Medical Center, Utrecht University, 3584 CT, Utrecht, the Netherlands. Electronic address: a.spelier-2@umcutrecht.nl.

Förderung

  • Horizon 2020 European Innovation Council Fast Track to Innovation
  • Dutch Cystic Fibrosis Foundation
  • Horizon 2020 Framework Programme

Zitieren

APA

Kroes, S., Zaidi, L., Sonneveld-van Kooten, H. N., Winkel, L., De Boeck, K., Amaral, M., van der Ent, C. K., Beekman, J. M., Spelier, S., & HIT-CF Organoid Study group (2026). A functional comparison of vanzacaftor/tezacaftor/deutivacaftor and elexacaftor/tezacaftor/ivacaftor in patient-derived intestinal organoids with rare CFTR variants. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2026.06.002

Vancouver

Kroes S, Zaidi L, Sonneveld-van Kooten HN, Winkel L, De Boeck K, Amaral M, et al. A functional comparison of vanzacaftor/tezacaftor/deutivacaftor and elexacaftor/tezacaftor/ivacaftor in patient-derived intestinal organoids with rare CFTR variants. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2026.06.002

BibTeX
@article{Kroes2026,
  author = {Kroes, Suzanne and Zaidi, Lara and Sonneveld-van Kooten, Heleen N and Winkel, Lianne and De Boeck, Kris and Amaral, Margarida and van der Ent, Cornelis K and Beekman, Jeffrey M and Spelier, Sacha and HIT-CF Organoid Study group, HIT-CF Organoid Study group},
  title = {A functional comparison of vanzacaftor/tezacaftor/deutivacaftor and elexacaftor/tezacaftor/ivacaftor in patient-derived intestinal organoids with rare CFTR variants},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2026.06.002}
}
Kostenlos starten →